Title : Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).

Pub. Date : 2007 Apr

PMID : 17409801






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Preclinical studies have suggested that celecoxib, a cyclooxygenase-2 inhibitor, has antitumor activity in NSCLC and can enhance the activity of EGFR inhibitors. Celecoxib epidermal growth factor receptor Homo sapiens